Best Kinase Inhibitor for leukemia, myeloid, chronic-phase
2 Kinase Inhibitor drugs indicated for leukemia, myeloid, chronic-phase, ranked by our independent rating. The current highest-rated is danziten. Compare them with all treatments for leukemia, myeloid, chronic-phase or the full Kinase Inhibitor class. Not medical advice — always consult a professional.
Top kinase inhibitor for leukemia, myeloid, chronic-phase: 1. Danziten · 2. Tasigna
| # | Drug | Rating | Type | Typical price | |
|---|---|---|---|---|---|
| 1 | Danziten | 72/100 | Prescription | — | View → |
| 2 | Tasigna | 68/100 | Prescription | — | View → |
Full ranking · 2 drugs
Frequently asked
- What is the best kinase inhibitor for leukemia, myeloid, chronic-phase?
- By our independent rating, danziten currently ranks highest among Kinase Inhibitor drugs used for leukemia, myeloid, chronic-phase. Ratings are based on FDA regulatory (recall-safety) data — always consult a professional.
- Which kinase inhibitor drugs treat leukemia, myeloid, chronic-phase?
- pharmaranks lists 2 Kinase Inhibitor products indicated for leukemia, myeloid, chronic-phase, per FDA drug-label data — each independently rated and ranked above.
- How are these ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.
